Holen Sie sich die Stockscreener-App
5.16
3.83%
0.20
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLDB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$4.96
Offen:
$5.02
24-Stunden-Volumen:
291.10K
Relative Volume:
1.05
Marktkapitalisierung:
$198.17M
Einnahmen:
$14.79M
Nettoeinkommen (Verlust:
$-102.44M
KGV:
-0.8354
EPS:
-6.1766
Netto-Cashflow:
$-91.73M
1W Leistung:
-3.01%
1M Leistung:
-11.51%
6M Leistung:
-39.48%
1J Leistung:
+114.58%
1-Tages-Spanne:
$4.94
$5.38
1-Wochen-Bereich:
$4.61
$5.515
52-Wochen-Spanne:
$2.44
$15.05
Solid Biosciences Inc Stock (SLDB) Company Profile
Firmenname
Solid Biosciences Inc
Sektor
Branche
Telefon
617-337-4680
Adresse
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Vergleichen Sie SLDB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| SLDB | 5.14 | 198.17M | 14.79M | -102.44M | -91.73M | -6.1766 |
| VRTX | 449.09 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 749.38 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 587.39 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.66 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.77 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-15 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-06-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-03-28 | Eingeleitet | William Blair | Outperform |
| 2024-03-15 | Eingeleitet | Citigroup | Buy |
| 2024-03-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-07-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-05-27 | Eingeleitet | Jefferies | Buy |
| 2021-03-16 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | Eingeleitet | Barclays | Overweight |
| 2021-01-08 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-11 | Eingeleitet | Evercore ISI | Outperform |
| 2019-08-29 | Herabstufung | Citigroup | Neutral → Sell |
| 2019-08-19 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | Herabstufung | Goldman | Neutral → Sell |
| 2019-02-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2019-02-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | Eingeleitet | Citigroup | Sell |
| 2018-09-06 | Eingeleitet | Credit Suisse | Neutral |
Alle ansehen
Solid Biosciences Inc Aktie (SLDB) Neueste Nachrichten
Cantor Fitzgerald Brokers Reduce Earnings Estimates for SLDB - MarketBeat
Solid Biosciences Reports Increased Losses Amid R&D Focus - TipRanks
(SLDB) Investment Analysis - Stock Traders Daily
Litecoin Climbs 10% In Rally - Investing.com
Is Solid Biosciences (NASDAQ:SLDB) In A Good Position To Invest In Growth? - Simply Wall St
Perceptive Advisors LLC's Strategic Acquisition in Solid Bioscie - GuruFocus.com
Vestal Point Capital, LP Increases Stake in Solid Biosciences Inc. - GuruFocus.com
FY2024 Earnings Estimate for SLDB Issued By Chardan Capital - MarketBeat
Solid Biosciences to Present at the Jefferies London Healthcare Conference - GlobeNewswire
Solid Biosciences CEO to Present at Jefferies London Healthcare Conference | SLDB Stock News - StockTitan
Solid Biosciences' SWOT analysis: DMD therapy stock faces pivotal moment - Investing.com India
Solid Biosciences' SWOT analysis: DMD therapy stock faces pivotal moment By Investing.com - Investing.com UK
JPMorgan Chase & Co. Lowers Solid Biosciences (NASDAQ:SLDB) Price Target to $12.00 - MarketBeat
HC Wainwright Analysts Decrease Earnings Estimates for SLDB - MarketBeat
Research Analysts Issue Forecasts for SLDB FY2024 Earnings - MarketBeat
We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate - Yahoo Finance
Solid Biosciences Inc. (NASDAQ:SLDB) Receives $15.67 Consensus Target Price from Brokerages - MarketBeat
Solid Biosciences (NASDAQ:SLDB) Given Buy Rating at HC Wainwright - MarketBeat
Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates - The Manila Times
Solid Biosciences: SGT-003 Trial Shows Promise, $171M Cash Runway Despite Wider Q3 Loss | SLDB Stock News - StockTitan
Senhwa Biosciences announces first patient dosed in the Phase I/II study of Silmitasertib in children and young adults with relapsed refractory solid tumors. - PR Newswire
Where are the Opportunities in (SLDB) - Stock Traders Daily
Exosome Therapies on the Rise as 70+ Major Companies Driving Development in the Field | DelveInsight - The Malaysian Reserve
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Millennium Management LLC Reduces Stake in Solid Biosciences Inc - GuruFocus.com
Sow Good to Hold Third Quarter 2024 Conference Call on Thursday, November 14, 2024 at 10:00 a.m. ET - The Manila Times
Solid Biosciences to Participate at the Truist Securities BioPharma Symposium - GlobeNewswire
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Global Exosome Market to Surge at a Tremendous CAGR of ~20% by 2030 | DelveInsight - GlobeNewswire
Duchenne Muscular Dystrophy Therapeutics Market Trends, Growth Insights, and Forecasts 2033 - WhaTech
WRN inhibitor IDE-275 gains IND clearance for phase I study in MSI-high tumors - BioWorld Online
IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors - BioSpace
(SLDB) Proactive Strategies - Stock Traders Daily
Pillar Biosciences Receives CPT® Code for FDA Approved oncoReveal™ CDx Pan-Cancer Solid tumor IVD Kit - PR Newswire
Solid Biosciences CMO sells $18,999 in stock - Investing.com India
Solid Biosciences CMO sells $18,999 in stock By Investing.com - Investing.com Canada
Insider Selling: Solid Biosciences Inc. (NASDAQ:SLDB) Insider Sells 2,923 Shares of Stock - MarketBeat
Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences - Quantisnow
Seraxis gains IND clearance for islet replacement therapy - BioWorld Online
(SLDB) Trading Signals - Stock Traders Daily
Solid Biosciences Inc (SLDB) did well last session? - US Post News
Keeping an Eye on Solid Biosciences Inc (SLDB) After Insider Trading Activity - Knox Daily
Cubist Systematic Strategies LLC Sells 74,908 Shares of Huron Consulting Group Inc. (NASDAQ:HURN) - Defense World
Cubist Systematic Strategies LLC Has $368,000 Stock Position in Metropolitan Bank Holding Corp. (NYSE:MCB) - Defense World
Cubist Systematic Strategies LLC Makes New $378,000 Investment in Cryoport, Inc. (NASDAQ:CYRX) - Defense World
Great Lakes Dredge & Dock Co. (NASDAQ:GLDD) Shares Sold by Cubist Systematic Strategies LLC - Defense World
Cubist Systematic Strategies LLC Makes New $362,000 Investment in Anterix Inc. (NASDAQ:ATEX) - Defense World
Aegon Ltd. (NYSE:AEG) Stake Raised by Cubist Systematic Strategies LLC - Defense World
SG Americas Securities LLC Lowers Stock Position in Pool Co. (NASDAQ:POOL) - Defense World
Lindsay Co. (NYSE:LNN) Shares Sold by Cubist Systematic Strategies LLC - Defense World
Cubist Systematic Strategies LLC Sells 23,029 Shares of The St. Joe Company (NYSE:JOE) - Defense World
Finanzdaten der Solid Biosciences Inc-Aktie (SLDB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Solid Biosciences Inc-Aktie (SLDB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kahn Clare | Director |
Jun 07 '24 |
Buy |
7.67 |
1,100 |
8,442 |
1,100 |
| Ganot Ilan | Director |
May 02 '24 |
Sale |
10.33 |
462 |
4,772 |
9,507 |
| Ganot Ilan | Director |
Jan 29 '24 |
Sale |
7.99 |
139 |
1,111 |
8,416 |
| PERCEPTIVE ADVISORS LLC | Director |
Jan 11 '24 |
Buy |
5.53 |
3,410,713 |
18,861,243 |
6,833,539 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jan 11 '24 |
Buy |
5.53 |
904,160 |
5,000,005 |
4,192,216 |
| Tan Kevin | CFO & Treasurer |
Jan 09 '24 |
Sale |
8.20 |
3,935 |
32,267 |
9,308 |
| Ganot Ilan | Director |
Jan 03 '24 |
Sale |
5.30 |
1,142 |
6,052 |
8,167 |
| Cumbo Alexander | President and CEO |
Dec 04 '23 |
Sale |
2.77 |
11,757 |
32,516 |
17,439 |
| Howton David T | Chief Operating Officer |
Dec 04 '23 |
Sale |
2.78 |
5,367 |
14,920 |
7,684 |
| Herzich Paul | Chief Technology Officer |
Dec 04 '23 |
Sale |
2.77 |
2,968 |
8,232 |
4,270 |
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):